Health
Novavax Approved by FDA in Covid-19 fight
By Dana Malcolm
Staff Writer
June 16, 2022 – COVID-19 vaccine: Novavax has received full support from the US Food and Drug Administration’s Advisory Committee which has recommended that it be approved for Emergency Use Authorization.
The decision was made on June 7th with all 21 members of the advisory committee voted in favor.
Despite the support, the committee was concerned that Novavax testing had not been done against any of the newer variants, because of this they said the study was “less relevant to the current epidemiology of SARS-CoV-2”.
The FDA says vaccine efficacy against mild, moderate, and severe COVID-19 over a follow-up of 2.5 months after full vaccination with Novavax was 90.4 percent but it was not possible to assess sustained efficacy longer than that.
The FDA will need to conduct more reviews and get the go-ahead from the Centers for Disease Control CDC before the vaccine will be available for home use